Left atrial appendage closure after a hospital admission for gastrointestinal bleeding in patients anticoagulated for atrial fibrillation.

Authors

Carlos Del Toro Esperón, Alberto Contreras Muñoz, Jaime Nevado Portero, Martín Ruiz Ortiz, Alejandro Isidoro Pérez Cabeza, Dolores Mesa Rubio, Lucas Barreiro Mesa, Rafael González Manzanares, Alejandro Recio Mayoral, Alejandro Reina Moreno, Javier Torres Llergo, Ana María Martínez Rodríguez, Laura Jordán Martínez, Ismael Arco Adamuz, Aurora María Martínez Ballesta, Víctor Manuel López Espinosa, José Luis Delgado Prieto, Leopoldo Fernández Ruz, Ana Delia Ruiz Duthil, Cristina Cánovas Galindo, Sara Corpas Pérez, Livia Gheorge, Mauricio Urgiles Ortiz, María Teresa García García, Jesús Aceituno Cubero, Gregorio Soto Rojas, Beatriz Girela Pérez, Sara Ballesteros Pradas, Virginia Pérez Ramirez, Almudena Valle Alberca, Susana Pérez Córdoba, José Javier Sánchez Fernández, Beatriz Calvo Bernal, Antonio Enrique Gómez Menchero, Carmen Lluch Requerey, Ana Del Río Lechuga, Juan José Serrano Silva

Published in

Revista espanola de enfermedades digestivas. Sep 30, 2026. Epub Sep 30, 2026.

Abstract

There are no "real world" data on the actual impact of percutaneous left atrial appendage closure (LAAC) programs in the management of thromboembolic prevention after a hospital admission for gastrointestinal bleeding (GIB) in anticoagulated patients with atrial fibrillation (AF). We evaluated the utilization, predictors, and clinical outcomes of LAAC following GIB-related hospitalizations.
The multicenter PERSEO registry retrospectively enrolled consecutive anticoagulated AF patients discharged alive after a GIB (2021-2022) across all public Andalusian hospitals with LAAC programs. Baseline features and clinical outcomes were compared between LAAC and medical management using multivariable logistic, and time-dependent Andersen-Gill and Cox regression models.
Among 1041 patients (median age 82 years, 48.7% male), only 70 (6.7%) underwent LAAC, at a median of 5 months post-discharge. LAAC was independently associated with younger age, previous bleeding, angiodysplasia, lower diastolic blood pressure, aspirin or direct oral anticoagulant use at admission, and tertiary referral-center care. LAAC was associated with a lower hazard of recurrent composite events (stroke/transient ischemic attack, systemic embolism, major or clinically relevant non-major bleeding, or death -HR 0.57, 95% CI 0.37-0.89, p=0.013) and with a lower hazard of all-cause mortality (HR 0.40, 95% CI 0.22-0.72, p=0.002).
In real-world clinical practice, LAAC was infrequently used after hospitalization for GIB in anticoagulated patients with AF, being selectively reserved for specific clinical phenotypes. Nevertheless, this strategy was associated with a lower risk of adverse outcomes after adjusting for measured confounders. These findings should be interpreted cautiously given the observational design of the study.

PMID:
42813932
Bibliographic data and abstract were imported from PubMed on 30 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.